Sempere A, Jarque I, Guinot M, Palau J, García R, Sanz G F, Gomis F, Pérez-Sirvent M L, Senent L, Sanz M A
Department of Hematology, La Fe University Hospital, Valencia, Spain.
Leuk Lymphoma. 1993 Dec;12(1-2):103-8. doi: 10.3109/10428199309059577.
The main clinical, morphological, cytochemical, immunological features and therapy results of eleven patients diagnosed as acute myeloblastic leukemia M0 (AML-M0) are reported here. There were no clinical characteristics, abnormalities on physical examination or initial laboratory parameters that distinguished these eleven patients. Bone marrow aspirates were hypocellular in four patients. The leukemic cells were undifferentiated by light microscopy and myeloperoxidase (MPO) and/or Sudan Black B (SBB) stains were negative in all cases. Myeloid differentiation antigens were present on the leukemic cells of all eleven patients, whereas B and T cell markers were clearly negative except for CD4 and CD7 antigens. Whatever the treatment employed survival was very short. Eight of the eleven patients were treated and two achieved complete remission (CR) but only one of them is alive in continuous CR. Our results like those previously reported, suggest that AML-M0 patients have a very poor prognosis with standard induction therapies and should perhaps be considered for experimental therapeutic approaches.
本文报告了11例被诊断为急性髓系白血病M0(AML-M0)患者的主要临床、形态学、细胞化学、免疫学特征及治疗结果。这11例患者没有可与其他患者相鉴别的临床特征、体格检查异常或初始实验室参数。4例患者骨髓穿刺显示细胞减少。白血病细胞在光镜下未分化,所有病例的髓过氧化物酶(MPO)和/或苏丹黑B(SBB)染色均为阴性。所有11例患者的白血病细胞均存在髓系分化抗原,而除CD4和CD7抗原外,B和T细胞标志物均明显为阴性。无论采用何种治疗方法,生存期都很短。11例患者中有8例接受了治疗,2例获得完全缓解(CR),但其中只有1例持续处于CR状态存活。我们的结果与先前报道的结果一样,提示AML-M0患者采用标准诱导疗法预后很差,或许应考虑采用实验性治疗方法。